Upstream Bio (UPB) Cash & Equivalents (2023 - 2026)

Upstream Bio has reported Cash & Equivalents for 4 years, with the latest figure at $96.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 35.63% year-over-year to $96.7 million; the trailing twelve-month figure through Mar 2026 stood at $96.7 million (up 35.63% YoY), and the FY2025 full-year result was $101.6 million, down 68.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $96.7 million, down from $101.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $321.0 million in Q4 2024, with the low at $25.8 million in Q4 2023.
• Average Cash & Equivalents over 4 years is $81.2 million, with a median of $47.3 million recorded in 2024.
• Year-over-year, Cash & Equivalents soared 1142.6% in 2024 and slumped 68.36% in 2025.
• Tracing UPB's Cash & Equivalents over 4 years: stood at $25.8 million in 2023, then soared by 1142.6% to $321.0 million in 2024, then tumbled by 68.36% to $101.6 million in 2025, then decreased by 4.78% to $96.7 million in 2026.
• The last three Cash & Equivalents figures came in at $96.7 million (Q1 2026), $101.6 million (Q4 2025), and $72.2 million (Q3 2025), per Business Quant data.

Peer Comparison